Molecular docking finds strong hybrid binding to multiple interleukins, suggesting improved therapeutic potential.
Chronic inflammation is mediated by interleukins (ILs), which are key in autoimmune, cardiovascular, and metabolic diseases. We report a novel hybrid molecule designed by combining pharmacophoric features of amentoflavone and vitamin D3. Molecular docking against IL-1β, IL-2, IL-4, IL-6, IL-8, IL-11, IL-12, and IL-17A demonstrated that the hybrid binds strongly across all IL targets, with affinities intermediate between amentoflavone (high potency, poor pharmacokinetics) and vitamin D3 (lower potency, favorable safety). ADMET prediction indicated improved drug-likeness, bioavailability, and reduced toxicity relative to amentoflavone. The hybrid scaffold integrates the hydrophobicity and rigidity of the steroid core with the polar, hydrogen-bonding capacity of the flavonoid moiety, representing a promising natural product-inspired NCE. These findings suggest potential for multi-target modulation of pro-inflammatory cytokines and support further experimental evaluation.
No takes yet. Share an insight, caveat, or question.
Ivan Vito Ferrari (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: